Stable And Sensorially Superior Topical Formulation

Itc Limited
Granted App No 201741002765 Patent 406294 Chemical

Patent information

IP India · live record
Application number
201741002765
Filing date
24 January 2017
Status
Granted
Legal status
Inforce
Publication number
30/2018
Publication type
INA
Invention field
Chemical
Patent number
406294
Grant date
09 September 2022
Next renewal due
24 January 2027

Abstract

STABLE AND SENSORIALLY SUPERIOR TOPICAL FORMULATION The instant disclosure provides a stable and sensorially superior (non-patchy, non oily/greasy, easily spreadable etc.) topical preparation with zinc oxide and boric acid as skin beneficiary actives in the form of emulsion with the combination of thickeners, humectants, oil components (hydrocarbons, emollients, bodying agents) and non-ionic emulsification system at a particular concentration. The present disclosure also relates to a process of preparation stable topical formulation.

Applicants

1
India
ITC LIMITED ITC LIFE SCIENCES & TECHNOLOGY CENTRE #3. 1st Main, Peenya Industrial Area, Phase-1, Bangalore 560 058, India

Inventors

3
India
KIRUBAKARAN, BalavaishnaviITC LIFE SCIENCES & TECHNOLOGY CENTRE #3. 1st Main, Peenya Industrial Area, Phase-1, Bangalore 560 058, India
India
MURALI, DeepaITC LIFE SCIENCES & TECHNOLOGY CENTRE #3. 1st Main, Peenya Industrial Area, Phase-1, Bangalore 560 058, India
India
PASUPULATE, SravanthiITC LIFE SCIENCES & TECHNOLOGY CENTRE #3. 1st Main, Peenya Industrial Area, Phase-1, Bangalore 560 058, India

Claims

12
1 A stable topical formulation comprising: a) zinc oxide; b) boric acid; c) steareth 21; d) steareth 2; e) at least one non-ionic thickener; f) at least one silicone; and g) at least one oil component, wherein the steareth 21 to the steareth 2 weight ratio is in the range of 1:0.3-1:3.
2 The formulation as claimed in claim 1, wherein the silicone is selected from the group consisting of dimethicone, polysilicone-11, phenyl trimethicone, trimethylsilylamodimethicone, stearoxytrimethylsilane, cyclomethicone, hexamethyldisiloxane, octamethyltrisiloxane, decamethylpentacyclosiloxane, dialkenylsilicones, dialkylsilicones, diaryl silicones, alkylarylsilicones, alkenylalkylsilicones, and mixtures thereof.
3 The formulation as claimed in claim 2, wherein the silicone is dimethicone.
4 The formulation as claimed in claim 1, wherein the oil component comprises at least one hydrocarbon, at least one emollient, and combinations thereof.
5 The formulation as claimed in claim 4, wherein the hydrocarbon is selected from the group consisting of petrolatum, paraffin wax, mineral oil, and combinations thereof.
6 The formulation as claimed in claim 4, wherein the emollient is selected from the group consisting of squalene, cyclopentasiloxane, dimethicone, derivatives, isopropyl myristate, isopropyl palmitate, isopropyl isostearate, C12-15 alkyl benzoate, fatty alcohols, and combinations thereof.
7 The formulation as claimed in claim 1, wherein the non-ionic thickener is selected from the group consisting of xanthan gum, guar gum, gum arabic, and combinations thereof.
8 The formulation as claimed in claim 7, wherein the non-ionic thickener is xanthan gum.
9 The formulation as claimed in claim 1, wherein the formulation has a pH in the range of 7.0-8.0.
10 A stable topical formulation comprising: a) zinc oxide having a weight percentage in the range of 0.5-3% with respect to the formulation; b) boric acid having a weight percentage in the range of 0.5-5% with respect to the formulation; c) steareth 21 having a weight percentage in the range of 0.9-2.7% with respect to the formulation; d) steareth 2 having a weight percentage in the range of 0.9-2.7% with respect to the formulation; e) at least one non-ionic thickener having a weight percentage in the range of 0.5-0.75% with respect to the formulation; f) at least one silicone having a weight percentage in the range of 2-3% with respect to the formulation; and g) at least one oil component having a weight percentage in the range of 20-30% with respect to the formulation, wherein the steareth 21 to the steareth 2 weight ratio is in the range of 1:0.3-1:3.
11 A process for the preparation of a stable topical formulation as claimed in claim 1, comprising steps of: a) contacting at least one non-ionic thickener and water to obtain water phase; b) contacting at least one oil component with steareth 21 and steareth 2 to obtain oil phase; c) contacting the water phase and the oil phase followed by homogenization to obtain a first mixture; and d) contacting zinc oxide and boric acid with first mixture to obtain stable topical formulation, wherein steareth 21 to steareth 2 weight ratio is in the range of 1:0.3-1:3.
12 The process as claimed in claim 11, comprising steps of: a) contacting at least one non-ionic thickener and water to obtain a dispersion, followed by heating the dispersion till the dispersion attains a a temperature in the range of 70 - 75 °C to obtain a water phase; b) contacting at least one oil component with steareth 21 and steareth 2 followed by heating the mixture at a temperature in the range of 70-75 0C to an obtain oil phase; c) contacting the water phase and the oil phase at a temperature in the range of 70-75 0C followed by homogenization for a period in the range of 5-30 minutes at a stirring speed in the range of 5000-7000 rpm to obtain a first mixture; and d) contacting zinc oxide and boric acid with the first mixture, followed by stirring at a speed in the range of 70-75 rpm at a temperature in the range of 25-30 0C to obtain stable topical formulation. , Description:As Attached

Specification

Show full textCollapse

Claims:1. A stable topical formulation comprising: a) zinc oxide; b) boric acid; c) steareth 21; d) steareth 2; e) at least one non-ionic thickener; f) at least one silicone; and g) at least one oil component, wherein the steareth 21 to the steareth 2 weight ratio is in the range of 1:0.3-1:3. 2. The formulation as claimed in claim 1, wherein the silicone is selected from the group consisting of dimethicone, polysilicone-11, phenyl trimethicone, trimethylsilylamodimethicone, stearoxytrimethylsilane, cyclomethicone, hexamethyldisiloxane, octamethyltrisiloxane, decamethylpentacyclosiloxane, dialkenylsilicones, dialkylsilicones, diaryl silicones, alkylarylsilicones, alkenylalkylsilicones, and mixtures thereof. 3. The formulation as claimed in claim 2, wherein the silicone is dimethicone. 4. The formulation as claimed in claim 1, wherein the oil component comprises at least one hydrocarbon, at least one emollient, and combinations thereof. 5. The formulation as claimed in claim 4, wherein the hydrocarbon is selected from the group consisting of petrolatum, paraffin wax, mineral oil, and combinations thereof. 6. The formulation as claimed in claim 4, wherein the emollient is selected from the group consisting of squalene, cyclopentasiloxane, dimethicone, derivatives, isopropyl myristate, isopropyl palmitate, isopropyl isostearate, C12-15 alkyl benzoate, fatty alcohols, and combinations thereof. 7. The formulation as claimed in claim 1, wherein the non-ionic thickener is selected from the group consisting of xanthan gum, guar gum, gum arabic, and combinations thereof. 8. The formulation as claimed in claim 7, wherein the non-ionic thickener is xanthan gum. 9. The formulation as claimed in claim 1, wherein the formulation has a pH in the range of 7.0-8.0. 10. A stable topical formulation comprising: a) zinc oxide having a weight percentage in the range of 0.5-3% with respect to the formulation; b) boric acid having a weight percentage in the range of 0.5-5% with respect to the formulation; c) steareth 21 having a weight percentage in the range of 0.9-2.7% with respect to the formulation; d) steareth 2 having a weight percentage in the range of 0.9-2.7% with respect to the formulation; e) at least one non-ionic thickener having a weight percentage in the range of 0.5-0.75% with respect to the formulation; f) at least one silicone having a weight percentage in the range of 2-3% with respect to the formulation; and g) at least one oil component having a weight percentage in the range of 20-30% with respect to the formulation, wherein the steareth 21 to the steareth 2 weight ratio is in the range of 1:0.3-1:3. 11. A process for the preparation of a stable topical formulation as claimed in claim 1, comprising steps of: a) contacting at least one non-ionic thickener and water to obtain water phase; b) contacting at least one oil component with steareth 21 and steareth 2 to obtain oil phase; c) contacting the water phase and the oil phase followed by homogenization to obtain a first mixture; and d) contacting zinc oxide and boric acid with first mixture to obtain stable topical formulation, wherein steareth 21 to steareth 2 weight ratio is in the range of 1:0.3-1:3. 12. The process as claimed in claim 11, comprising steps of: a) contacting at least one non-ionic thickener and water to obtain a dispersion, followed by heating the dispersion till the dispersion attains a a temperature in the range of 70 - 75 °C to obtain a water phase; b) contacting at least one oil component with steareth 21 and steareth 2 followed by heating the mixture at a temperature in the range of 70-75 0C to an obtain oil phase; c) contacting the water phase and the oil phase at a temperature in the range of 70-75 0C followed by homogenization for a period in the range of 5-30 minutes at a stirring speed in the range of 5000-7000 rpm to obtain a first mixture; and d) contacting zinc oxide and boric acid with the first mixture, followed by stirring at a speed in the range of 70-75 rpm at a temperature in the range of 25-30 0C to obtain stable topical formulation. , Description:As Attached

Documents

Sign in to open
Application documents
1 Form 5 [24-01-2017(online)].pdf 24 Jan 2017
2 Form 3 [24-01-2017(online)].pdf 24 Jan 2017
3 Description(Complete) [24-01-2017(online)].pdf_321.pdf 24 Jan 2017
4 Description(Complete) [24-01-2017(online)].pdf 24 Jan 2017
5 Other Patent Document [20-03-2017(online)].pdf 20 Mar 2017
6 Form 26 [20-03-2017(online)].pdf 20 Mar 2017
7 Correspondence by Agent_Proof of Right-Form1_22-03-2017.pdf 22 Mar 2017
8 Correspondence by Agent_Power of Authorisation_22-03-2017.pdf 22 Mar 2017
9 201741002765-FORM 18 [19-01-2021(online)].pdf 19 Jan 2021
10 201741002765-Response to office action [20-09-2021(online)].pdf 20 Sep 2021
11 201741002765-FER.pdf 17 Oct 2021
12 201741002765-OTHERS [05-05-2022(online)].pdf 05 May 2022
13 201741002765-FORM 3 [05-05-2022(online)].pdf 05 May 2022
14 201741002765-FER_SER_REPLY [05-05-2022(online)].pdf 05 May 2022
15 201741002765-PatentCertificate09-09-2022.pdf 09 Sep 2022
16 201741002765-IntimationOfGrant09-09-2022.pdf 09 Sep 2022
17 201741002765-FORM-27 [28-09-2026(online)].pdf 28 Sep 2026
18 201741002765-FORM-27 [28-09-2026(online)]-2.pdf 28 Sep 2026
19 201741002765-FORM-27 [28-09-2026(online)]-1.pdf 28 Sep 2026
Search strategy
1SearchreportE_22-03-2021.pdf

ERegister / renewals

Inforce
3rd Renewed 28 Nov 2022 Period 24 Jan 2019 – 24 Jan 2020 · CBR 47981 · Certificate 78314 ₹4,000
4th Renewed 28 Nov 2022 Period 24 Jan 2020 – 24 Jan 2021 · CBR 47981 · Certificate 78315 ₹4,000
5th Renewed 28 Nov 2022 Period 24 Jan 2021 – 24 Jan 2022 · CBR 47981 · Certificate 78316 ₹4,000
6th Renewed 28 Nov 2022 Period 24 Jan 2022 – 24 Jan 2023 · CBR 47981 · Certificate 78317 ₹4,000
7th Renewed 28 Nov 2022 Period 24 Jan 2023 – 24 Jan 2024 · CBR 47981 · Certificate 78318 ₹12,000
8th Renewed 11 Jan 2024 Period 24 Jan 2024 – 24 Jan 2025 · CBR 2347 · Certificate 7135 ₹12,000
9th Renewed 07 Nov 2024 Period 24 Jan 2025 – 24 Jan 2026 · CBR 67476 · Certificate 162899 ₹12,000
10th Renewed 07 Nov 2025 Period 24 Jan 2026 – 24 Jan 2027 · CBR 66422 · Certificate 78085 ₹12,000